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a b s t r a c t
Satellite cells are resident stem cells of skeletal muscle, supplying myoblasts for post-natal muscle
growth, hypertrophy and repair. Many regulatory networks control satellite cell function, which includes
EGF signalling via the ErbB family of receptors. Here we investigated the role of ErbB3 binding protein-1
(Ebp1) in regulation of myogenic stem cell proliferation and differentiation. Ebp1 is a well-conserved
DNA/RNA binding protein that is implicated in cell growth, apoptosis and differentiation in many cell
types. Of the two main Ebp1 isoforms, only p48 was expressed in satellite cells and C2C12 myoblasts.
Although not present in quiescent satellite cells, p48 was strongly induced during activation, remaining
at high levels during proliferation and differentiation. While retroviral-mediated over-expression of Ebp1
had only minor effects, siRNA-mediated Ebp1 knockdown inhibited both proliferation and differentiation
of satellite cells and C2C12 myoblasts, with a clear failure of myotube formation. Ebp1-knockdown
signiﬁcantly reduced ErbB3 receptor levels, yet over-expression of ErbB3 in Ebp1 knockdown cells did
not rescue differentiation. Ebp1 was also expressed by muscle cells during developmental myogenesis in
mouse. Since Ebp1 is well-conserved between mouse and chick, we switched to chick to examine its role
in muscle formation. In chick embryo, Ebp1 was expressed in the dermomyotome, and myogenic
differentiation of muscle progenitors was inhibited by speciﬁc Ebp1 down-regulation using shRNA
electroporation. These observations demonstrate a conserved function of Ebp1 in the regulation of
embryonic muscle progenitors and adult muscle stem cells, which likely operates independently of ErbB3
signaling.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Muscle satellite cells are the main resident stem cell population
in mature adult muscle (Mauro, 1961), and it has recently been
shown that they are indispensable for muscle regeneration
(reviewed in Relaix and Zammit, 2012). Satellite cells of the adult
derive from a population of muscle progenitors that can be traced
back to the dermomyotome of the embryonic somite. Muscle
progenitors are characterized by expression of the transcription
factors Pax3 and Pax7 (Gros et al., 2005; Kassar-Duchossoy et al.,
2005; Relaix et al., 2005). Once speciﬁed, these progenitors face a
dual choice, they can either proliferate, or exit cell cycle to
terminally differentiate into contractile muscle cells. Myogenic
speciﬁcation and differentiation require the sequential activation
of the myogenic regulatory factors (Myf5, MyoD, Myogenin and
Mrf4). During development, the process is continuous, with a
balance between proliferation and differentiation of muscle pro-
genitor cells essential to maintain the growth of skeletal muscle.
Some muscle progenitors remain undifferentiated however, and
will give rise to satellite cells. During the post-natal period,
satellite cells are highly active and generate myoblasts that
differentiate to supply myonuclei for muscle growth (Moss and
Leblond, 1971; White et al., 2010). In adult muscle, satellite cells
are normally mitotically quiescent. In response to different stimuli
(e.g. injury), satellite cells become activated, proliferate extensively
and then differentiate and fuse with each other to form new
myoﬁbres, or fuse to damaged myoﬁbres to repair them (Relaix
and Zammit, 2012). Satellite cell self-renewal also ensures that a
viable stem cell pool is maintained (Collins et al., 2005). During
myogenic progression, equilibrium between satellite cell prolifera-
tion and differentiation is again required, to ensure efﬁcient
muscle repair and maintenance. As in embryonic muscle progeni-
tors, this balance is controlled by similar molecules and signaling
pathways (Bjornson et al., 2012; Knopp et al., 2013; Mourikis et al.,
2012; Ono et al., 2011; Schuster-Gossler et al., 2007; Vasyutina
et al., 2007; Wen et al., 2012). Investigating how satellite cells
are regulated is imperative for understanding their functions of
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maintenance and repair in healthy muscle, for example after
sports injury, as well as providing insight as to why muscle wastes
in pathologies such as muscular dystrophies (Morgan and Zammit,
2010).
Multiple growth factors including HGF, FGF, and IGF have been
shown to regulate satellite cells (Ten Broek et al., 2010). There is
evidence that the EGF-family of ligands also participates in control-
ling satellite cell function, since they express all ErbB (ErbB1, 2,
3 and 4) receptors during activation, where ErbB2 signaling acts to
protect satellite cells from apoptosis (Golding et al., 2007). In vitro,
the ErbB3 receptor and its ligand Neuregulin, have different effects
onmyogenic progression. Neuregulin inhibits myogenin expression
in L6 myoblasts, and retains cells in a proliferative stage (Ford et al.,
2003). However, this same signaling pathway in myotubes pro-
motes differentiation and muscle growth via protein synthesis
(Hellyer et al., 2006; Kim et al., 1999). Similarly, Neuregulin
produced by neural crest cells prevents precocious differentiation
of skeletal muscle progenitor cells during muscle development, via
ErbB3 receptor signaling (Van Ho et al., 2011).
ErbB3 binding protein-1 (Ebp1) is a potential regulator of ErbB3
signaling, and is implicated in cell growth, apoptosis and differ-
entiation in many cell types. Ebp1 is ubiquitously expressed,
localizing to both nucleus and cytoplasm, and was originally
identiﬁed as a cell cycle speciﬁcally modulated nuclear protein of
38 kDA, designated p38-2G4 (Radomski and Jost, 1995). Ebp1 is a
member of the proliferation-associated PA2G4 gene family, which
is highly conserved throughout evolution, and is structurally
homologous to the type II methionine aminopeptidases but with-
out methionine aminopeptidase activity (Kowalinski et al., 2007a,
2007b; Monie et al., 2007). Further, Ebp1 has a C-terminal
extension containing motifs important for binding proteins and
RNA. Ebp1 interacts with proteins including ErbB3, the androgen
receptor (AR), Sin3A, PKR, and AKT, binds mRNAs such as those for
bcl2 and AR (Bose et al., 2006; Zhou et al., 2010a) and ribosomal
RNA (Squatrito et al., 2004). This ability to bind diverse proteins
and RNA in a cell type-dependent manner likely explains the
differing effects that Ebp1 can exert on cell growth, apoptosis and
differentiation.
Ebp1 encodes two alternatively spliced isoforms, p48 and p42,
with different functions (Liu et al., 2006). The predominant p48
isoform can promote cell proliferation, differentiation or cell
survival, and localizes to both cytoplasm and nucleus (Kim et al.,
2010; Kwon and Ahn, 2011; Liu et al., 2006). In cancer cell lines (e.
g. glioblastoma), the p48 isoform is highly expressed and can
promote cancer growth, migration and cell survival. In these cells,
Ebp1 promotes polyubiquitination and degradation of the tumor
suppressor p53 by facilitating the interaction between the E3
ligase HDM2 and p53 (Kim et al., 2010). The shorter p42 isoform
lacks the N-terminal 54 amino acids which may be important for
stabilization and nuclear localization (Monie et al., 2007; Squatrito
et al., 2004). As a consequence, p42 protein is generally less
abundant, predominantly resides in the cytoplasm and is able to
bind ErbB3 (Liu et al., 2006).
Ebp1 was identiﬁed as an ErbB3 binding protein in a yeast two-
hybrid screen (Yoo et al., 2000). Ebp1 binds unphosphorylated
ErbB3, the inactivated form of the receptor. In the presence of
Neuregulin, Ebp1 dissociates from the receptor and translocate to
the nucleus, where it forms a multicomplex protein, including
Sin3A, Rb and HDAC2 (Xia et al., 2001; Zhang et al., 2005a, 2003).
This complex functions as a transcriptional repressor of genes
regulated by E2F1 and the AR. Due to this transcriptional repressor
activity on genes such as E2F1, AR, and AGR2 involved in cancer
progression, Ebp1 was also proposed to act as a tumor suppressor
(Zhang et al., 2002, 2010; Zhang and Hamburger, 2004, 2005).
Moreover, over-expression of Ebp1 by down-regulating ErbB
signaling transduction in breast cancer cells is able to inhibit cell
growth induced by Neuregulin (Lessor et al., 2000; Yu et al., 2007;
Zhang et al., 2005b; Zhou et al., 2010b). These data suggest an
oncogenic function of the longer p48 isoform and a tumor
suppressor activity of the p42.
Here we investigated the role of Ebp1 in regulating muscle
stem cells. Although not present in quiescent satellite cells, Ebp1
was strongly induced during activation and remained at high
levels during proliferation and differentiation. Retroviral-
mediated over-expression of Ebp1 had only minor effects, but
Ebp1 knockdown by siRNA inhibited both proliferation and differ-
entiation of satellite cells and C2C12 myoblasts, with a failure of
myotube formation. Interestingly, while ErbB3 receptor levels
were signiﬁcantly reduced by knocking down Ebp1, over-
expression of ErbB3 was unable to rescue the differentiation defect
in such Ebp1 knockdown cells. We also examined the role of Ebp1
in developmental myogenesis, and found that Ebp1 was expressed
in muscle cells in both mouse and chicken embryos. However,
Ebp1 and ErbB3 were expressed in distinct cell populations in the
HH19 chick embryo, precluding physical interaction, since Ebp1
was expressed in muscle progenitors in dermomyotome, while
ErbB3 was present in myotome. Thus as in mouse, it appears that
Ebp1 operates independently of ErbB3 receptor signalling to
regulate myoblasts. Speciﬁc down-regulation of Ebp1 in chick
dermyomotome inhibited muscle progenitor differentiation, and
this effect occurred when cells exit the proliferative state and
enter terminal differentiation.
Results
Ebp1 is expressed in proliferating and differentiated C2 and satellite cells
We ﬁrst examined Ebp1 expression in C2C12 cells, which are
immortalized myoblasts derived from adult mouse muscle (Blau
et al., 1983; Yaffe and Saxel, 1977). Proliferating C2C12 myoblasts
were cultured at low density in proliferation medium, and when
conﬂuent, switched to differentiation medium. Under such culture
conditions, C2C12 myoblasts align on day 1 (D1) and fuse to form
myotubes (D2) that increase in size and nuclear content over-time
(D3) (Fig.1A). RNA and proteinwere extracted fromproliferating and
differentiating (D1–D3) C2C12 cells and analyzed for Ebp1 expres-
sion by quantitative RT-PCR, using myogenin expression to monitor
differentiation (Fig. 1B) and western blot analysis (Fig. 1C). Ebp1
mRNA was highly expressed in proliferating myoblasts, but levels
then dropped during myogenic differentiation (D1–D3) (Fig. 1B).
We used a polyclonal antibody that recognizes a common
epitope (aa: 200–300) of the p42 and p48 isoforms (ab33613).
Western blot analysis showed that only a band corresponding to
the p48 isoform was present (Fig. 1C). p48 was highly expressed in
proliferating C2C12 myoblasts and throughout differentiation
(Fig. 1C). Immunostaining of C2C12 myoblasts revealed the dis-
tribution of Ebp1 in individual proliferating (Fig. 1D and E) and
differentiated (Fig. 1F) C2C12 cells. Co-immunostaining for Ebp1
and MyoD revealed robust expression of Ebp1 in both the nucleus
and the cytoplasm of proliferating cells (Fig. 1D). However, while
present in the nucleus, Ebp1 immunostaining was weak in
nucleoli, as identiﬁed by the nucleolar protein Nucleophosmin
(NPM) (Fig. 1E). Later, Ebp1 was robustly expressed in C2C12
myotubes, although the immunosignal appeared less in the
nucleus than cytoplasm (Fig. 1F). Ebp1 expression in C2C12 was
conﬁrmed with a second polyclonal antibody (ABE43) able to
recognize the N-terminal part of Ebp1. ABE43 revealed Ebp1
localization in both nucleus and cytoplasm of proliferating and
differentiating C2C12 myoblasts (Fig. 1G–I).
To investigate the expression proﬁle of Ebp1 in primary murine
satellite cells, myoﬁbres were isolated from the Extensor Digitorum
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Fig. 1. Ebp1 is expressed in proliferating and differentiated C2C12 myoblasts. (A) C2C12 were maintained in proliferation medium, or switched to differentiation medium for
1 (D1), 2 (D2) or 3 (D3) days and RNA and protein collected at each time point to analyze Ebp1 expression. (B) Ebp1 and Myogenin were analyzed by quantitative RT-PCR.
(C) Western blot showing the presence of the Ebp1–p48 isoform in proliferating and differentiated C2C12 myoblasts from three independent samples (Exps. 1–3). Data are
mean7SEM from three independent experiments where an asterisk denotes a signiﬁcant difference (po0.05) from the levels in proliferating cells using an unpaired two-
tailed Student's t-test. (D and E) Proliferating and (F) differentiated C2C12 cells were ﬁxed and co-immunostained for Ebp1 (ab33613) and either MyoD (D), Nucleophosmin
(NPM) (E) or MyHC (F) and counterstained with DAPI. Ebp1 is expressed in both the nucleus and the cytoplasm of proliferating C2C12 (D and E) and myotubes (F). (G–I)
Proliferating and differentiated C2C12 cells immunostained with a second Ebp1 antibody (ABE43) able to recognize the N-terminal region of Ebp1 and co-immunostained
with MyoD (G), NPM (H) or MyHC (I), better illustrates the nuclear and cytoplasmic localization in myotubes (I). Scale bar equals 50 mm.
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Longus (EDL) muscle of adult mice (8–12 week old). Muscle ﬁbers
with their associated satellite cell were cultured, ﬁxed and
co-immunostained at different time points to monitor Ebp1
expression during myogenic progression (quiescence, activation,
proliferation and commitment to differentiation) (Zammit et al.,
2004). Immediately after isolation (T0), myoﬁbres co-immuno-
stained for Pax7 to identify quiescent satellite cells did not
contain detectable amounts of Ebp1 (Fig. 2A). However, after
24 h (T24) in culture, Ebp1 was clearly present in Pax7þve
activated satellite cells (Fig. 2B). Later (T72), Epb1 was robustly
expressed in all satellite cells co-immunostained with either Pax7
(Fig. 2C), or Myogenin to identify cells committed to differentia-
tion (Fig. 2D).
To examine Ebp1 expression during myoblast fusion and myo-
tube formation, we used expanded plated satellite cells. Myoﬁbres
were cultured on matrigel to allow activation, migration and
proliferation of satellite cell from isolated muscle ﬁbers. After 3
days, myoﬁbres were removed and plated satellite cells were either
maintained in proliferation, or switched to differentiation medium
for 12, 24 or 48 h to stimulate myotube formation. RNA and protein
were extracted from proliferating and differentiating satellite cells
and analyzed for Ebp1 expression by quantitative RT-PCR (Fig. 2E)
and western blot (Fig. 2F). While Ebp1 expression decreased
signiﬁcantly at the mRNA level during differentiation (Fig. 2E), the
protein remained robustly expressed (Fig. 2F). Co-immunostaining
for Ebp1 and Pax7 revealed expression of Ebp1 in both the nucleus
and the cytoplasm of proliferating satellite cell-derived myoblasts
(Fig. 2G). As in C12C12 myoblasts, Ebp1 immunostaining was
weaker in the nucleolus, as identiﬁed by Nucleophosmin (Fig. 2H).
Co-immunostaining of differentiated satellite cell-derived myotubes
(D48h) for Ebp1 and MyHC antibodies conﬁrmed the presence of
Ebp1 in myotubes (Fig. 2I). Ebp1 expression in the nucleus and
cytoplasm of proliferating and differentiated satellite cells was also
conﬁrmed with the second polyclonal antibody (ABE43) recognizing
the N-terminal part of Ebp1 (Fig. S1).
Ebp1 over-expression does not affect myogenic progression in satellite
cells
For analysis of Ebp1 function in satellite cells, we ﬁrst performed
over-expression studies. Satellite cells associated with a myoﬁbre were
infected with a retrovirus generating a bicistronic message encoding
the cDNA of the murine p48 isoform of Ebp1, together with eGFP (RV
Ebp1) or with a retrovirus encoding just eGFP acting as a control for
retroviral infection (RV Control). To conﬁrm over-expression of Ebp1 in
infected satellite cell, ﬂoating myoﬁbres were co-immunostained for
Ebp1 and eGFP 24 h post-infection (T48 in culture) (Fig. 3A). As
expected, eGFPþve infected satellite cells had stronger expression of
Ebp1, compared to uninfected satellite cells. After 72 h in culture (48 h
post-infection), co-immunostaining for eGFP and Pax7, or eGFP and
Myogenin, showed that over-expression of Ebp1 did not signiﬁcantly
change the proportion of satellite cells expressing Pax7, but slightly
reduced the proportion containing Myogenin (Fig. 3B).
To investigate whether Ebp1 over-expression could affect satellite
cell proliferation or fusion, we also infected expanded plated satellite
cell-derived myoblasts with RV Ebp1 or RV Control (Fig. 3C).
For proliferation analysis, infected satellite cells were cultured at
low density in proliferation medium and EdU was added for 2 h,
before cells were ﬁxed, and stained for EdU incorporation and eGFP
expression. Constitutive expression of Ebp1 did not affect the
proportion of satellite cell-derived myoblasts containing EdU
(Fig. 3D). To test myotube formation, infected satellite cells were
switched to differentiation medium and cultured for 2 days, then
ﬁxed and co-immunostained for eGFP and MyHC and the fusion
index calculated (Fig. 3E). Constitutive expression of Ebp1 did not
affect fusion of satellite cells into multinucleated myotubes.
Ebp1 knockdown inhibits proliferation and differentiation of satellite
cells
Since Ebp1 is strongly expressed in proliferating and differentiat-
ing satellite cells, we next examined the effects of siRNA-mediated
knockdown of Ebp1 on proliferation and myogenic progression.
Three different siRNA sequences targeting Ebp1 mRNA (siEbp1) and
a negative control siRNA (siControl), were tested by transfection into
proliferating C2 myoblasts, and the knockdown efﬁciency deter-
mined by a western blot (Fig. 4A). The most efﬁcient Ebp1 siRNA (♯2)
was selected and used on plated satellite cells. Proliferating satellite
cell-derived myoblasts were transfected with Ebp1 and control
siRNA and 48 h later, nuclear and cytoplasmic proteins extracted
and run on a western blot to conﬁrm that Ebp1 levels were
efﬁciently reduced in both nucleus and cytoplasm (Fig. 4B).
For proliferation analysis, satellite cell were cultured at low
density and pulsed with EdU for 2 h. Cells were then ﬁxed, stained
for EdU and DAPI and the percentage of proliferating (EdUþ) cells
calculated (Fig. 4C). Compared to control cells (siControl), knock-
down of Ebp1 (siEbp1) signiﬁcantly reduced the percentage of
proliferating satellite cells from a mean7SEM of 44.775.8% to
32.875.1%, showing that Ebp1 is necessary to maintain normal
proliferation. To determine if reduced Ebp1 levels could affect
myogenic differentiation, conﬂuent satellite cell-derived myo-
blasts were switched to differentiation medium for 2 days and
then co-immunostained for Pax7 (Fig. 4D) and Myogenin (Fig. 4E).
Reduction of Ebp1 induced a signiﬁcant increase in the percentage
of undifferentiated Pax7þve satellite cells from a mean7SEM of
40.974.0% to 52.874.1%, which correlated with a decrease in the
proportion of differentiating myogeninþve satellite cells from
66.474.3% to 51.572.6%. Finally, we tested the ability of Ebp1
knockdown satellite cells to fuse and form myotubes. Differen-
tiated cultures were immunostained for MyHC and calculation of
the fusion index revealed a signiﬁcant drop in cell fusion, from a
mean7SEM of 38.971.0% in controls to 22.371.5% in the Ebp1
knockdown satellite cells (Fig. 4F).
Stable Ebp1 knockdown C2 cell lines have reduced proliferation and
differentiation
To further examine Ebp1 function and its putative interactions
with the ErbB3 signaling pathway, we established stable C2 cell
lines producing shRNA against Ebp1, or against Luciferase for the
control cell line (C2-Luc-KD). Three different shRNA sequences
targeting Ebp1 mRNA were used to establish three separate cell
Fig. 2. Ebp1 is dynamically expressed in proliferating and differentiated primary satellite cell-derived myoblasts. (A–D) EDL myoﬁbres with their associated satellite cells
were immediately ﬁxed after isolation (T0) or cultured in plating medium for either 24 h (T24) or 72 h (T72) before ﬁxation and co-immunostaining for Ebp1 (ab33613), and
either Pax7 or Myogenin. (A) Ebp1 is not expressed in quiescent satellite cells at T0, as identiﬁed by Pax7 expression (arrowhead). However, Ebp1 expression is induced in
activated satellite cells by T24 (B) and is strongly maintained in all satellite cells at T72, whether they co-express Pax7 (C – arrowheads) or myogenin (D – arrowheads).
(E) Plated satellite cells were maintained in proliferation medium, or switched to differentiation medium for 12, 24 or 48 h (D12h, D24h and D48h) and RNA collected at each
time point to analyze Ebp1 and Myogenin expression by quantitative RT-PCR. Ebp1 levels dropped as satellite cell underwent myogenic differentiation. (F) Western blot
analysis conﬁrmed the presence of the Ebp1–p48 isoform in both proliferating and differentiated (D24h and D48h) satellite cells. Data are mean7SEM from three
independent experiments where an asterisk denotes a signiﬁcant difference (po0.05) from the levels in proliferating cells using a paired two-tail Student's t-test. (G–I)
Plated satellite cells were maintained in proliferation (G and H) or induced to differentiate (I), then ﬁxed and co-immunostained with Ebp1 (ab33613), and either Pax7 (G),
Nucleophosmin (NPM) (H) or MyHC (I). Ebp1 was expressed in both the nucleus and the cytoplasm of both proliferating Pax7þve satellite cells and MyHCþve myotubes.
Scale bar equals 50 mm.
N. Figeac et al. / Developmental Biology 386 (2014) 135–151138
N. Figeac et al. / Developmental Biology 386 (2014) 135–151 139
lines and the knockdown efﬁciency determined by western blot
(Fig. S2). Stable C2 line ♯1 had Ebp1 efﬁciently repressed, and so
was selected for further study, henceforth being termed C2-Ebp1-
KD. As with satellite cells, knockdown of Ebp1 also reduced C2C12
proliferation, since only a mean7SEM of 30.074.2% of C2-Ebp1-
KD myoblasts incorporated label after a 2 h EdU pulse, compared
to 62.571.6% in the control C2-Luc-KD cell line (Fig. 5A). RNA
from proliferating C2-Luc-KD and C2-Ebp1-KD cells was extracted
for quantitative RT-PCR to measure expression of Myf5 and
genes involved in cell cycle regulation (C-myc, Cyclin D1, D2,
p21, p27, p53 and Rb). Myf5 and CD2 expressions were signiﬁ-
cantly decreased in proliferating C2-Ebp1-KD myoblasts, while
CD1 and p21 levels increased, with the rest being unaffected
(Fig. S3).
Fig. 3. Over-expression of Ebp1 does not greatly affect myogenic progression in satellite cells. Satellite cells associated with a myoﬁbre were infected with retrovirus
containing the mouse cDNA of Ebp1 (RV Ebp1) or a control for retroviral infection (RV Control). RV Control and RV Ebp1 also contain an IRES-eGFP which allows visualization
of infected satellite cells. (A) Myoﬁbres and associated satellite cells were ﬁxed and co-immunostained for eGFP and Ebp1 (Ab33613) 24 h post-infection (T48). Infected
eGFPþve satellite cells (arrowhead) showed stronger expression of Ebp1 compared to uninfected eGFP-ve satellite cells (arrow). (B) After 72 h in culture (48 h post-
infection), infected satellite cells were ﬁxed and co-immunostained for eGFP, and either Pax7 or Myogenin. Constitutive expression of Ebp1 had a minor effect on the entry
into differentiation. (C) Plated expanded satellite cell-derived myoblasts were infected with RV Control and RV Ebp1 and maintained in proliferation medium, or induced to
undergo terminal differentiation. (D) Edu was added to the medium for 2 h, before satellite cell-derived myoblasts were ﬁxed and stained for Edu and eGFP. The percentage
of Eduþve cells from the pool of infected eGFPþve satellite cells was calculated. (E) Differentiated satellite cells were ﬁxed and immunostained for eGFP and MyHC and the
fusion index determined. Constitutive expression of Ebp1 did not affect the proliferative or fusion ability of plated satellite cell-derived myoblasts. Data are mean7SEM from
three mice where an asterisk denotes a signiﬁcant difference (po0.05) from control RV infection using a paired two-tail Student's t-test. Scale bar equals 50 mm.
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Incubation in mitogen-poor medium to stimulate differentia-
tion revealed a signiﬁcant drop in the percentage of myogeninþve
C2-Ebp1-KD myoblasts to a mean7SEM of 16.372.8%, compared
to 62.3.76.6% in the control C2-Luc-KD cell line (Fig. 5B). In
accordance with the reduction in Myogenin expression, C2-Ebp1-
KD cells also had a major fusion defect, with only a mean7SEM of
4.271.0% nuclei in MyHCþve myotubes compared to 36.471.6%
in the control cell line (Fig. 5C). To verify that the fusion defect was
not due to a lower density of cells, C2-Ebp1-KD cells were plated at
twice the normal density and after 4 days of differentiation, the
fusion defect was still evident (data not shown). RNA from control
and C2-Ebp1-KD cells were extracted after 5 days in differentiation
medium, and quantitative RT-PCR was used to measure expression
of myogenic regulatory factors (Myf5, MyoD and Myogenin),
Fig. 4. siRNA-mediated Ebp1 knockdown suppresses satellite cell proliferation and differentiation. Knockdown of Ebp1 was performed using siRNA transfection.
(A) Efﬁciency of three different siRNA sequences targeting Ebp1 mRNA was tested 2 days after transfection into C2C12 myoblasts using a western blot. (B) The most
efﬁcient siRNA (♯2) was then tested on plated satellite cell-derived myoblasts, with western blot analysis showing reduction of Ebp1 protein in both nucleus and cytoplasm.
(C) For analysis of the effects of Ebp1 knockdown on proliferation, satellite cell-derived myoblasts were transfected with either siControl or siEbp1 and 2 days later, pulsed
with EdU for 2 h, before cells were ﬁxed and stained for Edu and DAPI. Ebp1-knockdown signiﬁcantly decreased the percentage of proliferating satellite cells incorporating
EdU. (D–F) For analysis of the effects of knockdown of Ebp1 on differentiation, siControl and siEbp1-transfected satellite cell-derived myoblasts were switched to
differentiation medium when conﬂuent and cultured for 2 days before being ﬁxed and immunostained for either Pax7 (D), Myogenin (E) or MyHC (F). SiRNA-mediated
knockdown of Ebp1 induced a signiﬁcant increase in the population of Pax7þve cells at the expense of Myogeninþve cells. Consistent with the reduction of differentiating
myogeninþve cells, Ebp1 knockdown also caused a large drop in the fusion index (F). Data are mean7SEM from three or four mice, where an asterisk denotes a signiﬁcant
difference (po0.05) from transfection with siControl using a paired two-tail Student's t-test. Scale bar equals 50 mm.
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MyHC, potential interacting proteins (Six1 and 4) and genes
known to be regulated by Ebp1 (C-myc, p53 and Rb). C2-Ebp1-
KD had a signiﬁcant increase in Myf5, Six1, C-Myc and p53
expression, and a reduction of Myogenin and MyHC (Fig. 5D).
MyoD, Six4 and Rb RNA levels were unchanged.
Ebp1 function is independent of ErbB3 signaling pathways
The ErbB3 receptor and its ligand Neuregulin are involved in
myoblast growth and differentiation (Kim et al., 1999). Due to the
ability of Ebp1 to interact with the ErbB3 receptor, it was important
to investigate if Ebp1 function in myoblasts was linked to ErbB3
signaling. First, we analyzed the expression pattern of ErbB3 in
proliferating and differentiated C2C12 myoblasts by quantitative
RT-PCR (Fig. 6A) and western blot analysis (Fig. 6B). At the mRNA
level, ErbB3 was not expressed in proliferating myoblasts or at day
1 of differentiation, but was induced after 2 days of differentiation
and increased at day 3 (Fig. 6A). A similar expression proﬁle for
ErbB3 was also found in plated satellite cell-derived myoblasts
using quantitative RT-PCR (Fig. S4). Expression of ErbB3 only in
Fig. 5. Stable Ebp1 knockdown inhibits proliferation and differentiation in C2C12 myoblasts. Stable control (C2-Luc-KD) and Ebp1 knockdown (C2-Ebp1-KD) cell lines were
created using shRNA. (A) A 2 h EdU pulse of proliferating cells revealed that proliferation of C2-Ebp1-KD was lower than in the control C2-Luc-KD cell line. (B and C) To
analyze differentiation, C2-Ebp1-KD and C2-Luc-KD cells were cultured for 5 days in differentiation medium, then ﬁxed and immunostained for either Myogenin (B) or
MyHC (C). C2-Ebp1-KD myoblasts exhibited a signiﬁcant reduction in the percentage of cells containing myogenin (B) and the ability to form multinucleated myotubes (C).
(D) C2-Luc-KD and C2-Ebp1-KD cells were cultured 5 days in differentiation medium, and expression of myogenic genes (Myf5, MyoD, Myogenin, MyHC, Six1 and Six4) and
genes known to be regulated by Ebp1 (C-myc, p53 and Rb) were analyzed by quantitative RT-PCR. C2-Ebp1-KD myoblasts had increased levels of Myf5, Six1, C-myc and p53
and lower levels of Myogenin and MyHC. Data are mean7SEM from three independent experiments where an asterisk denotes a signiﬁcant difference (po0.05) between
C2-Ebp1-KD and C2-Luc-KD using an unpaired two-tailed Student's t-test. Scale bar equals 50 mm.
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Fig. 6. Ebp1 function in myoblasts is independent of ErbB3 signaling. Wild type C2C12 were maintained in proliferation, or switched to differentiation medium for 1 (D1), 2 (D2) or 3
(D3) days and RNA and protein collected at each time point to analyze ErbB3 expression. (A) ErbB3 was strongly induced as cells entered differentiation and levels then increased
further. (B) Extracted proteins were analyzed by western blot with anti-ErbB3 antibody that showed that ErbB3 was induced and increased during differentiation. (C) Expression of
ErbB receptors and NRG1 in control C2-Luc-KD and C2-Ebp1-KD myoblasts after 5 days in differentiation medium was analyzed by quantitative RT-PCR. C2-Ebp1-KD myoblasts had
increased ErbB1 expression, but decreased levels of both ErbB2 and ErbB3, while NRG1 or ErbB4 were unaffected. (D and E)Wild type C2C12 were infected with RV Ebp1 or RV Control
andmaintained in proliferation (D) or switched to differentiation medium for 2 days (E). Expression levels of different myogenic regulatory factors (Myf5, MyoD andMyogenin), C-Myc,
ErbB3 and NRG1 were analyzed by quantitative RT-PCR. Over-expression of Ebp1 did not directly inﬂuence ErbB3 expression. (F–H) C2-Ebp1-KD myoblasts were infected with a
retroviral construct encoding ErbB3 (RV ErbB3) or RV Control and induced to differentiate. (F) ErbB3 was efﬁciently expressed as shown by quantitative RT-PCR and western blot.
(G) After 4 days in differentiation medium, cells were ﬁxed and immunostained with either Myogenin or MyHC to analyze differentiation. (H) Constitutive expression of ErbB3 (RV
ErbB3) did not rescue the differentiation or fusion defects in C2-Ebp1-KDmyoblasts. Data are mean7SEM from three independent experiments where an asterisk denotes a signiﬁcant
difference (po0.05) from proliferation (A), or controls (C–F and H) using an unpaired two-tail Student's t-test. Scale bar equals 50 mm.
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differentiated myoblasts was conﬁrmed at the protein level by
western blot (Fig. 6B), and immunostaining showed dispersed
patches of immunosignal on myotubes (data not shown).
Ebp1 has been shown to regulate gene expression by controlling
mRNA and protein stability. One of the genes controlled by Ebp1 is
ErbB2 (Ghosh et al., 2013; Lu et al., 2011), the most common partner
for ErbB3 activation (Graus-Porta et al.,1997). Therefore,we analyzed
if Ebp1 could inﬂuence expression of ErbB receptors or its ligand
Neuregulin1. C2-Ebp1-KD and control C2-Luc-KD cells were cultured
in differentiationmedium for 5 days and RNAwas then extracted and
used forquantitativeRT-PCR. In the absence of Ebp1, levels ofErbB3 in
C2-Ebp1-KD decreased by 80%, and those of ErbB2 by 20%, while
ErbB1 expression increased 2-fold (Fig. 6C). Neuregulin1 and ErbB4
expression levels were unaffected (Fig. 6C).
Since ErbB3 expression is affected in C2-Ebp1-KD myoblasts we
examined if Ebp1 could directly regulate ErbB3. We ﬁrst investi-
gated potential Ebp1–ErbB3 interactions in wild type C2C12
myoblasts. Myoblasts were infected with a retrovirus encoding
the mouse cDNA of Ebp1 (RV Ebp1), or an empty vector as a control
for retroviral infection (RV Control). RNA was harvested from cells
cultured in proliferation medium, or maintained in differentiation
medium for 2 days, and analyzed by quantitative RT-PCR. Over-
expression of Ebp1 in either proliferating (Fig. 6D) or differentiated
(Fig. 6E) wild type C2C12 myoblasts did not inﬂuence expression
of ErbB3 or Neuregulin1. As in satellite cell-derived myoblasts,
over-expression of Ebp1 did not affect myoblast differentiation, or
the levels of MyoD or Myogenin (Fig. 6E).
Ebp1 does not appear to directly regulate ErbB3 expression in
wild type C2 myoblasts. However, the differentiation defect could
be because ErbB3 is involved in myoblast fusion and is decreased
by 80% in C2-Ebp1-KD cells. We therefore performed a rescue
experiment by over-expressing the murine ErbB3 receptor in C2-
Ebp1-KD cells. Proliferating C2-Ebp1-KD myoblasts were infected
with a retrovirus encoding the mouse cDNA of ErbB3, or RV
Control. Cells were cultured for 4 days in differentiation medium
and analyzed by quantitative RT-PCR, western blot and immunos-
taining. The efﬁciency of ErbB3 over-expression was conﬁrmed by
quantitative RT-PCR and western blot (Fig. 6F). Infected C2-Ebp1-
KD myoblasts were ﬁxed and co-immunostained for Myogenin
and MyHC to analyze differentiation (Fig. 6G). Constitutive expres-
sion of ErbB3 in C2-Ebp1-KD cells did not affect the percentage of
cells containing Myogenin, and the fusion index remained at
approximately 2% (Fig. 6H).
Ebp1 is expressed in embryonic muscle progenitors during
developmental myogenesis
As similar signaling pathways are involved in both muscle
development and adult muscle regeneration, we also analyzed
Ebp1 expression in murine embryonic myoblasts. Embryos at E13.5
of development were cross-sectioned and co-immunostained for
Ebp1 (ab33613) and either Desmin as a general marker of muscle
cells, Pax7, Myogenin or MyHC (Fig. S5). As previously reported,
Ebp1 was broadly expressed, but particularly strongly in embryonic
Desminþve myoblasts at E13.5 (Fig. S5A-A′). Ebp1 was present
in both undifferentiated Pax7þve myoblasts (Fig. S5B-B′) and
Myogeninþve or MyHCþve differentiating myoblasts/myotubes
(Fig. S5C, C′, D and D′).
Mouse is not an ideal model to assess the role of Ebp1 during
developmental myogenesis, since only a germline knockout is
available (Zhang et al., 2008b). No conditional knockout allele
exists to our knowledge, which would be needed to test the effects
of Ebp1 absence speciﬁcally in muscle cells, and also any temporal
requirements. Therefore to examine the function of Ebp1 during
muscle formation, we switched to the chick embryo model, since
gene knockdown can be more targeted using electroporation to
deliver siRNA.
Crucially, sequence analysis using ClustalW2 from the COM-
PARE Database showed 84% homology at the amino acid level
between mouse Ebp1 (mEbp1) and chicken Ebp1 (cEbp1) protein
(Fig. 7A), suggesting functional conservation between mammals
and birds.
To examine the expression domain and dynamics of Ebp1 in
chicken embryos, we used in situ hybridization with an EST that
spans a portion of the cEbp1 mRNA (Fig. 7). At stage HH19 (3
days of development/37–40 somites), cEbp1 was expressed in both
somites and limb bud (Fig. 7B). cEbp1 was found co-localized with
Pax7 in the epithelial dermomyotome, prior to its Epithelial
Mesenchyme Transition (EMT) that generates resident muscle
progenitors, using transverse sections of hybridized embryos
immunostained for Pax7 and counterstained with DAPI (Fig. 7C–
F). At HH19, ErbB3 was also expressed in somites (Fig. 7G) and
cross-sections of hybridized embryos immunostained for Pax7
revealed expression in the primary myotome but not dermomyo-
tome (Fig. 7H–K). At this stage, the primary myotome is composed
of fully differentiated (i.e. MyHCþve), post-mitotic muscle ﬁbers.
This indicates that ErbB3 is expressed at a later stage of myogenic
differentiation. Since cEbp1 and ErbB3 are expressed in separate
domains in chick dermomyotome at this stage, they cannot
physically interact, supporting our observations in mouse that
Ebp1 can act independently of ErbB3.
At stage HH28 (5.5 days of development), resident muscle
progenitors have entered the myotome, as shown by the presence
of Pax7 within the muscle masses on transverse sections of
hybridized HH28 embryos immunostained for Pax7 (Fig. 7N–P
and S–U). Similarly to Pax7, cEbp1 transcripts were also now
observed in the myotome (Fig. 7L-P). While co-expression of Pax7
and cEbp1 could not be conﬁrmed by in situ hybridization, their
similar expression patterns at E3 and E5.5 indicate that cEbp1 is
likely to be expressed by resident muscle progenitors. At this
stage, cErbB3 was also expressed in the myotome (Fig. 7Q-U).
Knockdown of Ebp1 maintains progenitor cells in an undifferentiated
state during developmental myogenesis
To examine the role of Ebp1 in regulating the balance between
proliferation and differentiation in muscle progenitors in vivo,
cEbp1 was down-regulated by electroporating a vector expressing
shRNAmir (pRFPRNAiC-Ebp1) directed against cEbp1 mRNA,
together with RFP to identify targeted cells. To test the targeting
and efﬁciency of the cEbp1 shRNA, pRFPRNAiC-Ebp1 was electro-
porated in the dermomyotome at HH16 (2.5 days of develop-
ment). 24 h later at HH20, in situ hybridization revealed a clear
decrease in cEbp1 mRNA levels speciﬁcally in RFP-containing
electroporated cells (arrows Fig. 8A–C). As expected, cEbp1 expres-
sion was unaffected by electroporation of control shRNA
(pRFPRNaiC-luciferase) directed against the luciferase gene (arrows
Fig. 8D–F).
We then performed inter-limb electroporation of HH16 chick
embryos and targeted the dorsal dermomyotome, source of
muscle progenitor cells. Embryos were incubated for 3.5 days after
electroporation to reach HH28 (5.5 days of development) to
allow muscle progenitors to enter the myotome and undergo
myogenic differentiation. Electroporated cells containing shRNA
against Ebp1 or control shRNA against Luciferase were identiﬁed
by immunostaining for RFP (Fig. 8G-O). During differentiation,
progenitor cells sequentially express speciﬁc myogenic markers:
Pax7þve and Pax7þve/Myf5þve cells are proliferative, and con-
stitute the muscle progenitor population, while MyoDþve and
Myogeninþve cells are post-mitotic myogenic cells undergoing
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Fig. 7. Ebp1 is expressed in muscle progenitors during developmental myogenesis in chicken. (A) Chicken Ebp1 (cEbp1) and Mouse Ebp1 (mEbp1) amino acid sequence
alignment showing 84% homology, suggesting a conservation of protein function. (B and G) Whole-mount in situ hybridization of cEbp1 and cErbB3 on HH19 (3 days of
development) chick embryos showing that both genes are expressed in the somite. (C–F and H–K) Transverse section at the level of the dotted-line in (B) and
(G) respectively, immunostained for Pax7 to delimit the dermomyotome, with a DAPI counterstain. While cEbp1 mRNA is expressed in dermomyotome (arrow in C–F) and
co-localized with Pax7, cErbB3 is expressed mainly in the underlying myotome (H–K). (L and Q) Whole-mount in situ hybridization of cEbp1 and cErbB3 on HH28 (5.5 days
of development) chick embryos showing that both genes are expressed in the myotome. (M–P and R–U) Cross-section at the level of the dotted line in (L and Q) respectively
immunostained for Pax7 to mark the myotome and a DAPI counterstain. At this stage, both cEbp1 and cErbB3 are expressed in the myotome and co-localise with Pax7.
Dermomyotome (dm), Myotome (m), and Neural Tube (NT). Scale bars equal 20 μm for (C–F) and (H–K) and 50 μm for (M–P and R–U).
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terminal differentiation, resulting in MyHC expression (Manceau
et al., 2008; Picard and Marcelle, 2013).
We ﬁrst tested the effects of down-regulating cEbp1 by com-
paring the proportion of Pax7þve myogenic progenitors with the
proportion of MyHCþve differentiated cells (Fig. 8H). 3.5 days
after electroporation of control luciferase shRNA, a mean7SD of
31.270.9% RFPþve electroporated cells expressed Pax7, while
66.270.9% contained MyHC (Fig. 8L). However, electroporation
of Ebp1 shRNA led to a signiﬁcant increase in Pax7þve cells to
61.071.0%, which correlated with a decrease in the MyHCþve
population to 35.071.4% (Fig. 8H and L). Similar results were
observed using the early differentiation marker Myogenin, where
only 36.571.5% RFP/shRNA-Ebp1 cells expressed. Myogenin,
compared to 52.871.7% for the shRNA-luciferase control (Fig. 8I
and M). Thus, down-regulating Ebp1 inhibits differentiation of
muscle progenitor cells in the chick embryo, as it also does in
satellite cells from adult mouse.
To further identify the steps of myogenic progression
affected by the loss of Ebp1 function, we analyzed whether
Ebp1 plays a role in the expression of Myf5 in Pax7þve muscle
progenitors, as this is the ﬁrst sign of myogenic speciﬁcation
from multipotent progenitors. We quantiﬁed the ratio of
RFPþve/Pax7þve/Myf5þve cells versus RFPþve/Pax7þve/
Myf5-ve in the myotomal compartment 3.5 days after electro-
poration. No difference was observed when cEbp1 was down-
regulated using Ebp1 shRNA compared to luciferase shRNA,
Fig. 8. Ebp1 is required for myoblast differentiation during developmental myogenesis. (A–C) To down-regulate cEbp1 expression, pRFPRNAiC–Ebp1 was electroporated into
the dorsal dermomyotome of HH16 (2.5 days of development) chicken embryos. 24 h later at HH20, sections were immunostained for RFP protein from the pRFPRNAiC–
Ebp1 vector to mark those cells expressing the shRNA against cEbp1. RFP-containing cells showed a strong down-regulation of cEbp1 mRNA expression, as shown by in situ
hybridization. (D–F) cEbp1 mRNA expression was unaffected in RFP-containing cells after electroporation of a control vector containing a shRNA directed against luciferase.
(G) A low magniﬁcation transverse section co-immunostained for RFP/Myf5/Pax7 after 3.5 days from electroporation of a HH16 chicken embryo with pRFPRNAiC–Ebp1 to
down-regulate cEbp1. Cells electroporated in the dermomyotome at HH16 are integrated into the myotome compartment by HH28 (5.5 days of development) and are
identiﬁed with RFP (dotted-line). The boxed area shows the region from which cells were quantiﬁed for expression of the different markers. (H–K) Myotome cross-section
(dotted-line) co-immunostained for the myogenic markers MyHC/Pax7 (H), Myogenin/Pax7 (I), Myf5/Pax7 (J) and MyoD/Pax7 (K) used for counting the cell populations. (L–
O) corresponding quantiﬁcation highlighting the role of Ebp1 in myoblast differentiation in vivo. Data are mean7SD from three independent experiments where an asterisk
denotes a signiﬁcant difference (po0.05) using a paired two-tail Student's t-test.
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indicating that Ebp1 does not regulate the initiation of Myf5
expression (Fig. 8J and N). The next step in myoblast speciﬁca-
tion is the initiation of MyoD. Few dermomyotome-derived
cells co-express MyoD and Pax7 at 3.5 days after electropora-
tion under normal conditions. When Ebp1 was down-regulated
though, the proportion of MyoDþve/Pax7þve cells was
signiﬁcantly larger than with the control shRNA (Fig. 8K and
O). Thus, loss of normal Ebp1 function induces an accumulation
of the Pax7þve/MyoDþve cell population, suggesting
that Ebp1 promotes myogenic differentiation of muscle pro-
genitors by controlling the differentiation step after MyoD
activation.
Discussion
In this study, we investigated the function of the p48 isoform of
Ebp1 in controlling the balance between proliferation and differ-
entiation of embryonic myoblasts and adult muscle stem cells.
Ebp1 has been reported to be weakly expressed in skeletal muscle
(Squatrito et al., 2004), and Ebp1 expression was found to be
higher in activated than quiescent satellite cells on microarrays
(Pallafacchina et al., 2010). We found that Ebp1 protein was
present in muscle cells during developmental myogenesis in
mouse and chick. In adult mouse, Ebp1 was undetectable in
quiescent satellite cells, but induced following activation, and
maintained throughout myogenic progression including in large
mature multinucleated myotubes. Considering its robust expres-
sion throughout myogenic progression though, it was unsurprising
that retroviral-mediated constitutive Ebp1 expression had no
measurable effects on proliferation, and only a minor effect on
differentiation.
By contrast, down-regulation of Ebp1 reduced proliferation in
both satellite cell-derived myoblasts and stable Ebp1 knockdown
C2-Ebp1-KD cells. Reduced proliferation may be linked to the role
of Ebp1 in ribosome assembly (Squatrito et al., 2004), since
alterations of ribosome biogenesis can induce cell cycle arrest by
p53 dependent or independent mechanisms (Donati et al., 2012).
Yet, in proliferating C2C12 and satellite cells Ebp1 is only weakly
expressed in the nucleolus and expression of genes inﬂuenced by
perturbation of ribosome biogenesis (C-Myc, p53 and Rb) were
unaltered in proliferating C2-Ebp1-KD myoblasts. These results
suggest that Ebp1 is not playing a central role in ribosome
biogenesis in proliferating myoblasts. However, further investiga-
tions will be necessary to determine the mechanism whereby
Ebp1 affects muscle cell proliferation, especially since Ebp1 is well
conserved and also promotes cell proliferation and expansion even
in plants (Horvath et al., 2006).
Ebp1 knockdown also reduced the number of differentiated
cells, with myotube formation dramatically lower, and an
increased proportion of undifferentiated cells. The systematic
Ebp1 knockdown in stable C2-Ebp1-KD myoblasts had a similar
but stronger effect on myogenic differentiation, likely due to the
higher efﬁciency of shRNA-mediated knockdown. Interestingly,
MyoD, a known activator of myogenin, remained expressed. Ebp1
is able to bind ARE (AU-rich element) present in the 3′UTR of
mRNA (Bose et al., 2006). During differentiation, Myogenin mRNA
is stabilized by HuR protein that also binds to AREs located in the
3′UTR of the transcript (Figueroa et al., 2003). It will be interesting
to determine if Ebp1 can also directly bind and stabilize
Myogenin mRNA.
Ebp1 knockout mice display a temporary growth retardation,
but no obvious muscle defects have been reported (Zhang et al.,
2008b). Thus muscle growth may have been transiently compro-
mised in Ebp1/ mice. Phenotypes in satellite cells can be better
revealed when muscle is damaged, which then requires extensive
satellite cell input to regenerate, but the consequences of such
skeletal muscle injury in Ebp1/ mice have not been reported.
It was recently shown that neural crest-mediated Neuregulin1–
ErbB3 signaling is a candidate regulator of myogenesis, where
Neuregulin1 acts through ErbB3–PI3K–AKT signaling to maintain
myoblasts in the undifferentiated state (Van Ho et al., 2011). Ebp1
can interact with the inactive form of the ErbB3 receptor, but in
the presence of the ligand Neuregulin, Ebp1 dissociates from the
receptor and translocates to the nucleus. In cancer cells, Ebp1
over-expression reduces both ErbB2 expression and ErbB3 signal-
ing transduction (Zhang et al., 2008a). We investigated the
possibility that Ebp1 and ErbB3 act together to regulate muscle
differentiation. We ﬁrst conﬁrmed expression of ErbB3 in differ-
entiated satellite and C2 cells, and the increase in levels upon
myotube formation (Golding et al., 2007). We then analyzed ErbB
receptor expression in C2-Ebp1-KD myoblasts, and found a sig-
niﬁcant reduction in ErbB3 mRNA levels after 5 days of differentia-
tion. However, Ebp1 does not appear to directly regulate ErbB3,
since Ebp1 over-expression in both proliferating and differentiated
C2C12 myoblasts was unable to inﬂuence ErbB3 expression.
Speculatively, the decrease of ErbB3 may be attributed to the
inability of C2-Ebp1-KD myoblasts to differentiate and up-regulate
ErbB3 expression, rather than the lack of Ebp1. Moreover, consti-
tutive expression of ErbB3 did not rescue the differentiation defect
in C2-Ebp1-KD cells, again suggesting that Ebp1 is acting inde-
pendently of ErbB3. Nevertheless, we cannot exclude the possibi-
lity that C2-Ebp1-KD myoblasts are unable to activate downstream
ErbB3 signaling per se, explaining why exogenous ErbB3 is unable
to rescue differentiation.
In Drosophila, Ebp1 is expressed in myoblasts during muscle
development (data not shown), where Ebp1 can interact with the
transcription factor sine oculus. The vertebrate homologs of sine
oculus, Six1 and Six4, are expressed in embryonic muscle pro-
genitors and satellite cells and control expression of myogenic
regulatory factors (Myogenin and Mrf4) (Grifone et al., 2005;
Yajima et al., 2010). An attractive hypothesis for vertebrate muscle
progenitors therefore, is that Ebp1 controls myogenic differentia-
tion not through ErbB3, but by interacting with Six1/4. We found
that while Six4 expression was unaffected in differentiated C2-
Ebp1-KD cells, Six1 was increased. Six1 has been shown to
promote satellite cell differentiation (Le Grand et al., 2012;
Yajima et al., 2010) but over-expression of Six1 in C2C12 myoblasts
can also lead to retardation of myogenic differentiation (Li et al.,
2013). Further investigations are necessary to evaluate the poten-
tial interaction between Ebp1 and Six1/4 and effects of Six1 up-
regulation in C2-Ebp1-KD cells.
Further support for an ErbB3-independent role of Ebp1 in
myoblast differentiation derives from the differential expression
domains of ErbB3 and Ebp1 in chick somites. Such differential
localization between ErbB3 and p48 Ebp1 isoform has also been
described in hippocampal neurones (Kwon and Ahn, 2011). While
the p42 Ebp1 isoform has been shown to bind ErbB3 upon EGF
stimulation (Yoo et al., 2000) and dissociate from ErbB3 by
Neuregulin stimulation, the p48 isoform does not bind ErbB3,
regardless of growth factor stimulation (Liu et al., 2006). Again,
this reinforces the notion of p48 acting as a signaling molecule
independently of ErbB3.
To easily target and manipulate Ebp1 levels during develop-
mental myogenesis, we employed electroporation of Ebp1 shRNA
into chick embryonic dermomyotome in vivo. cEbp1 down-
regulation inhibited myocyte differentiation and increased the
population of Pax7þve precursors. A cascade of genes is activated
during myocyte differentiation in development, where Pax3/Pax7
expressing cells commit to myogenesis and sequentially express
Myf5, MyoD, Myogenin and then MyHC. Myostatin has been
shown to regulate the balance between Pax7 and Myf5 during
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myogenic speciﬁcation (Manceau et al., 2008). We found that Ebp1
regulates the next step, where cells exit the cell cycle (Pax7þve/
Myf5þve) to become post-mitotic MyoD-expressing myocytes.
In summary we show that Ebp1 is robustly expressed in
myoblasts during both developmental and regenerative myogen-
esis where it acts to maintain proliferation and promote myogenic
differentiation. This role of Ebp1 in myogenesis however, appears
independent of its well-characterized interactions with the ErbB3
receptor.
Materials and methods
Ethics statement
Mice were bred and experimental procedures carried out in
accordance with British law under the provisions of the Animals
(Scientiﬁc Procedures) Act 1986, as approved by the King's College
London Ethical Review Process committee.
Myoﬁbre isolation and culture of primary satellite cells
Adult C57BL10 mice (8–12 weeks old) were killed by cervical
dislocation and the EDL muscle isolated and digested in 0.2%
collagenase type 1 (sigma) for 2 h at 37 1C (Collins and Zammit,
2009). Myoﬁbres were cultured in plating medium DMEM-
GlutaMAX (Sigma) supplemented with 10% horse serum (HS),
0.5% chicken embryonic extract (CEE) and 1% penicillin–strepto-
mycin (Sigma) at 37 1C in 5% CO2. To prepare plated satellite cell-
derived myoblasts, cells were allowed to migrate from isolated
myoﬁbres cultured in proliferation medium (DMEM-GlutaMAX,
20% fetal bovine serum (FBS), 10% HS, 1% CEE, 10 ng/ml bFGF, and
1% penicillin–streptomycin) on Matrigel. 3 days later, myoﬁbres
were removed and satellite cells re-plated on Matrigel and main-
tained and expanded in proliferation medium. For some experi-
ments, satellite cells were switched to differentiation medium
(DMEM-GlutaMAX supplemented with 5% FBS or 5% HS and 1%
penicillin–streptomycin). Myoﬁbres and plated satellite cell-
derived myoblasts were ﬁxed with warm 4% paraformaldehyde/
PBS.
Culture of C2C12 myoblasts
C2C12 myoblasts (Yaffe and Saxel, 1977) were maintained in
proliferation in DMEM supplemented with L-glutamine (1% v/v), 10%
FBS and 1% penicillin–streptomycin. For differentiation, C2C12 were
plated on Matrigel in low-mitogen medium (DMEM supplemented
with 1% L-glutamine, 5% HS and 1% penicillin–streptomycin). C2C12
myoblasts were ﬁxed with warm 4% paraformaldehyde/PBS.
For proliferation analysis, cells were incubated 2 h at 37 1C in
proliferation medium containing 5-ethynyl-2′-deoxyuridine (EdU)
at a ﬁnal concentration of 10 mM (Click-iT EdU Imaging Kits,
Invitrogen).
Immunostaining
Fixed myoﬁbres, plated satellite cells and C2C12 myoblasts
were permeabilised with 0.5% Triton X-100/PBS for 5 min at room
temperature and blocked with 10% goat serum/10% swine serum in
PBS for 30 min at room temperature. Primary antibodies were
applied over-night at 4 1C and were visualized with ﬂuorochrome-
conjugated secondary antibodies (Molecular Probes) used at 1/500
for 1 h at room temperature. Preparations were then mounted in
Dako mounting medium containing 4, 6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories).
Immunoblot analysis
Primary antibodies were applied over-night at 4 1C and were
visualized with HRP-conjugated secondary antibodies applied for
1 h at room temperature.
Antibodies used for immunostaining and immunoblot
Immunostaining: monoclonal anti-myogenin (F5D-s, Develop-
mental Studies Hybridoma Bank (DSHB), 1/10), anti-Pax7 (Pax7-s,
DSHB, 1/10), anti-MyHC (M20-c DSHB, 1/250), anti-MyoD1 (5.8a,
DakoCytomation, 1/50), rabbit polyclonal anti-eGFP (Invitrogen, 1/
1000), anti-Ebp1 (ab33613, abcam, 1/400), anti-Ebp1 N-terminus
(Millipore ABE43, 1/400), anti-Nucleophosmin (ab10530, abcam, 1/
2000), and anti-Desmin (clone D33, DAKO, 1/100).
Immunoblot: monoclonal anti-β-tubulin (E7-c, DHSB, 1/2000),
anti-ErbB3 (2F12, Millipor, 1/200), rabbit polyclonal anti-Ebp1
(ab33613, abcam, 1/2000), goat polyclonal anti-lamin A/C (N-18,
Santa Cruz, 1/1000). HRP-conjugated secondary antibodies, anti-
mouse IgG (NA931V, Ge Healthcare, 1/5000), anti-rabbit IgG
(NA934V, Ge Healthcare, 1/5000), and anti-goat IgG (ab19, abcam,
1/1000).
Retroviral expression vectors
The retroviral backbone pMSCV-puro (Clontech) was modiﬁed
to replace the puromycin selection gene with an IRES-eGFP in
order to create pMSCV–IRES-eGFP, which served as control
(Zammit et al., 2006). Ebp1–p48 isoform and ErbB3 mouse cDNA
were cloned by PCR using the following primers:
p48F: AGGAAGATGTCGGGCGAAGACGAGC; p48R: TCAGTCCC-
CAGCTCCATTC; ErbB3 F: GCCACCATGAGTGCGATTGGGACTCTG;
and ErbB3 R: TCAAATTCTCTGGGCGTTAGC. The retroviral RNAi-
Ready pSIREN-RetroQ vector (clonetech) was used to create the
C2-Ebp1-KD and the control C2-Luc-KD (luciferase) stable lines.
The shRNA sequence against Ebp1: GGTATTGCCTTTCCTACCA TTC
AAGAGATGGTAGGAAAGGCAATACC; and Luciferase: GTGCGTTGCT
AGTACCAACTTCAAGAGAGTTGGTACTAGCAACGAC.
Stable lines were selected in cell culture medium containing
puromycin at 3 mg/ml. Retrovirus were then packaged in 293T cells
using standard methods.
siRNA-mediated gene knockdown
Transfection of siRNA into primary satellite cell was performed
using Lipofectamine RNAiMAX and Stealth siRNA (Invitrogen Life
Technologies). The SiRNA sequence (5′-CCCUUUGAGCCUGACCU-
GUACAAGU-3′) was used to knockdown Ebp1 expression. Control
siRNAs were supplied by Invitrogen Life Technologies. Cells were
transfected with 20 nM siRNA for 5 h at 371 in DMEM-GlutaMAX
supplemented with 30% FBS and 1% CEE.
Quantitative RT-PCR
Cells were cultured in 6-well plates in proliferation or differ-
entiation medium. Total RNA was extracted using the RNeasy Kit
(Qiagen) and cDNA prepared from 1 mg of RNA with the QuantiTect
Reverse Transcription Kit with genomic DNA wipeout (Qiagen).
QPCR was performed on an Mx3005PQPCR system (stratagene)
with Brillant II SYBR green reagents and ROX reference dye
(Stratagene). Primers for TBP (F:5′-ATCCCAAGCGATTTGCTG-3′,
R:5′-CCTGTGCACACCATTTTTCC-3′), GAPDH (F:5′-GTGAAGGTCGGT
GTGAACG-3′, R:5′-ATTTGATGTTAGTGGGGTCTCG-3′), Myf5 (F:5′-
TGAGGGAACAGGTGGAGAAC-3′, R:5′-AGCTGGACACGGAGCTTTTA-
3′), MyoD (F:5′-GCTCCACTATGCTGGACAGG-3′, R:5′-AGCACTACAGT
GGCGACTCA-3′), Myogenin (F:5′-CTACAGGCCTTGCTCAGCTC-3′
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R:5′-AGATTGTGGGCGTCTGTAGG-3′), MyHC (F: 5′-GTCCAAAGC-
CAACAGTGAAG-3′, R:5′-CTTCTGTTTCCATTCTGCCA-3′), Ebp1 (F:5′-
TGACCTTGGGGTTCATGTGG-3′, R:5′-CTGGTTTCCAGGTTTGACCAG-
3′), Six1 (F:5′-TTAAGAACCGGAGGCAAAGA-3′, R:5′-GGGGGTGAGA
ACTCCTCTTC-3′), Six4 (F:5′-CAGGTCAGCAACTGGTTCAA-3′, R:5′-
AGAGAGGCTGAGGTTGGTGA-3′), NRG1 (F:5′-TCCACGACTGGGAC-
CAGC-3′, R:5′-TGTAGAAGCTGGCCATTACG-3′), C-Myc (F:5′-CCTA
GTGCTGCATGAGGAGA-3′, R:5′-GTTGTGCTGGTGAGTGGAGA-3′),
p53 (F: 5′-AGCACAGGACCCTGTCACC-3′, R: 5′-CACGTCTTCGC-
CAGCTGG-3′), and Rb (F: 5′-GCCTCTCCAGGGTAACCATA-3′, R: 5′-
GAAGGCGTGCACAGAGTGTA-3′),
Cyclin D1 (F:5′-TCTTTCCAGAGTCATCAAGTGTG-3′ and R: 5′-
GCTGGCTCCTTCCTCTTTG-3′), Cyclin D2 (F:5′-CTGTGGCATTTA-
CACCGACAAC and R:5′-TTCCAGTTGCAATCATCGAC-3′), p21 (F:5′-
GTACTTCCTCTGCCCTGCTG-3′ and R:5′-TCTGCGCTTGGAGTGA-
TAGA-3′), p27 (F:5′-GTGGACCAAATGCCTGACTC-3′ and R:5’-TCTT
CTGTTCTGTTGGCCT-3′), ErbB1 (F:5′-AGACCTGCCCAGCTGGCAT-
CAT-3′ and R:5′-TGGCCCAGATGGCCACACTTCAC-3′), ErbB2 (F:5′-
TTTGTAAACACTGTACCTTGGG-3′ and R:5′-TGCAGTTGACACACTG
GGTG-3′), ErbB3 (F:5′-CCCTCACATGCACAACTTCAG-3′ and R:5′-
ACTTATGTAGACACGCCCAGC-3′), and ErbB4 (F:5′-CGGGACTCT
GGGTCTGGGGG-3′ and R:5′-GCGCAAGGCTCGGTACTGCT-3′). Rela-
tive expression between C2-Ebp1-KD and control C2-Luc-KD
myoblasts was measured in three replicates and signiﬁcance was
tested using Student's t-test.
Embryo staining
Embryos (E13.5) were preﬁxed with 4% paraformaldehyde
over-night at 4 1C, washed in PBS, incubated successively in 5%
sucrose solution, 15% sucrose solution and ﬁnally positioned in
15% sucrose/7% gelatin solution. Embryos were frozen in liquid
nitrogen and cryosectioned at 10 mm thickness. For immunos-
taining, cryosections were incubated at 90 1C for 10 min in
Vector: H-3300 low pH antigen unmasking solution. Sections
were then blocked in blocking solution (5% goat serum, 0.5%
BSA, and 0.2% triton X-100/PBS) for 30 min. Primary antibodies
Ebp1 ((ab33631): 1/100; Desmin: 1/100; Pax7: 1/5, Myogenin:
1/10 and MyHC:1/10) were prepared in blocking solution and
incubated over-night at 4 1C. Sections were washed three times
for 10 min each in PBS with 0.05% Tween 20. Secondary anti-
bodies (Molecular Probes) (1/500) were prepared in blocking
solution and applied to sections for 1 h at room temperature.
Preparations were then washed three times for 10 min each in
0.05% Tween/PBS and mounted in Dako mounting medium
containing 4, 6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories).
In situ hybridization and tissue sections
Whole mount in situ hybridization on chick embryos was
performed as described previously (Gros et al., 2009). The in situ
hybridization probes used were ChEST875d16 for cEbp1 and
ChEST998a17 for cErbB3 from BBRC Chick EST Database. In situ
hybridization was performed on whole-mount, and embryos then
embedded in gelatine/sucrose solution, sectioned at 20 mm using a
Cryostat (Leica CM3050S) and immunostained for Pax7 and
mounted in Fluoromount DAPI (Southernbiotech).
Plasmids and in vivo electroporation
Newly formed somites were electroporated as described
(Delﬁni et al., 2009) with electrodes positioned so that the dorsal
domain of the somite, which gives rise to the dermomyotome,
was electroporated. We used the pRFPRNAiC vector to down-
regulate Chick Ebp1 expression (Das et al., 2006). This vector
contains an RFP reporter gene and expresses, under a chick U6
promoter, two shRNAmir in tandem to create pRFPRNAiC-Ebp1.
The two 22 nucleotides targets sequences (CGCTTTGATACTATGC-
CATTTA and GAGAGTTTGTTGCACAGTTCAA) were chosen using
the design tool “shRNA Target Finder” at https://www.genscript.
com/ssl-bin/app/rnai. We veriﬁed that electroporation of the
siRNA down-regulated cEbp1 transcripts. An unrelated shRNA
targeting the luciferase gene was used as control: a procedure
followed for other genes expressed in somites (Gros et al., 2009;
Rios et al., 2011).
Antibodies, immunochemistry and confocal analysis on chicken
embryos
For immunochemistry on sections, the following antibodies
were used: Mouse monoclonal antibodies against Pax7 or MyHC
MF20 (DSHB); Rabbit polyclonals against Myf5, MyoD or Myo-
genin (kindly provided by Bruce Patterson); and Rabbit polyclonal
against RFP (Abcam). Immunostained sections were examined
using a Zeiss Z1 apotome.
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